| Similar Articles |
|---|
 |
The Motley Fool
December 1, 2008
Brian Orelli |
Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now.   |
BusinessWeek
September 23, 2010
Rob Waters |
Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed. |
The Motley Fool
November 28, 2007
Brian Orelli |
Stem Your Expectations of Stem-Cell Discoveries Making "stem" cells out of skin cells isn't all it's cracked up to be. The recent discovery has a long way to go before it can catch up to the research currently being done with stem cells. |
The Motley Fool
August 27, 2007
Brian Orelli |
Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note. |
The Motley Fool
August 31, 2007
Brian Orelli |
A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending. |
The Motley Fool
April 14, 2008
Brian Orelli |
Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost. |
The Motley Fool
November 15, 2011
Brian Orelli |
When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells. |
The Motley Fool
November 14, 2008
Brian Orelli |
Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells. |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works. |
The Motley Fool
December 16, 2011
Brian Orelli |
Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function. |
The Motley Fool
August 19, 2010
Brian Orelli |
The Mice Can Walk! Remember you're essentially buying a lottery ticket investing in this or any other unproven early stage biomedical technology. |
The Motley Fool
May 26, 2009
Brian Orelli |
A Less-Risky Stem Cell Play Life Technologies is a clear leader in stem cell reagents. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals. |
The Motley Fool
December 22, 2009
Brian Orelli |
Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year |
The Motley Fool
August 2, 2010
Brian Orelli |
Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today. |
Bio-IT World
April 2006 |
Virtual Stem Cell Laboratory Goes Live Children's Hospital in Boston's Virtual Stem Cell Laboratory web site allows online visitors to manipulate and investigate a "living" culture of embryonic stem cells. |
HHMI Bulletin
May 2010
Sarah C.P. Williams |
Lab-Grown Liver New cell culture system solves problem of growing liver cells. |
The Motley Fool
January 20, 2012
Dan Caplinger |
Can Geron Recover in 2012? Let's look at this year's prospects for this company. |
The Motley Fool
February 2, 2005
Rich Duprey |
Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
A Boost for Broken Hearts? The Institute of Regenerative Medicine in Barbados is convinced that stem cells from fetuses can repair cardiac damage. |
The Motley Fool
May 3, 2005
Charly Travers |
Is Geron a Rule Breaker? At the forefront of stem cell research, can the company live up to its lofty potential? Geron's science is hot. Its stock is not. |
The Motley Fool
July 26, 2004
Brian Gorman |
Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
May 2, 2011
Brian Orelli |
StemCells Up for All the Right Reasons Federal funding doesn't matter for most stem cell companies. |
The Motley Fool
September 28, 2007
Brian Orelli |
Side Effects No Match for This Tag Team Seven large drugmakers have come together to try and find genetic variations that cause medications to have serious side effects in some patients, but not in others. |
The Motley Fool
April 17, 2008
Brian Lawler |
The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver. |
The Motley Fool
July 14, 2011
Rich Smith |
What's All the Fuss About Stem Cells? Stocks are up on news of Sweden's miracle meatball. Over the weekend, Swedish researchers announced the successful transplant of an artificial trachea to a patient whose own organ had been ravaged by cancer. |
Scientific American
December 2008
Tim Hornyak |
Turning Back the Cellular Clock: A Farewell to Embryonic Stem Cells? Shinya Yamanaka discovered how to revert adult cells to an embryonic state. These induced pluripotent stem cells might soon supplant their embryonic cousins in therapeutic promise |
BusinessWeek
July 26, 2004
Arlene Weintraub |
The Stem-Cell Flap: Simmer Down Advocates are overstating stem cells' near-term ability to treat grave illnesses. In doing so, they not only distort the science; the hopes they raise among many people who are sick today are also sure to be dashed. |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
Chemistry World
September 11, 2013
Emma Stoye |
Call to overhaul liver toxicity testing Outdated assays for monitoring liver health could have caused dozens of drug candidates to be wrongly scrapped during development, according to new research. |
Reactive Reports
Issue 64
David Bradley |
Stem to Sperm New research shows that stem cells from human bone marrow can be converted into early-stage sperm. The discovery could lead to novel fertility treatments in the long-term. |
The Motley Fool
October 12, 2010
Travis Hoium |
Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial. |
The Motley Fool
August 24, 2007
Brian Orelli |
Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it. |
BusinessWeek
June 27, 2005
Arlene Weintraub |
Stem Cells To Go ViaCell's goal is to mass-produce stem cells from umbilical cord blood. |
Fast Company
March 2008
Elizabeth Svoboda |
Eureka? Alan Trounson, the new president of California's stem-cell agency, talks about the science, the opposition, and his qualms about working with embryos. |
Bio-IT World
July 15, 2003
Kevin Davies |
Stem Cell Suicide The International Society for Stem Cell Research must engage in a political discourse to salvage the hope of embryonic stem cell research. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
June 21, 2005
Brian Gorman |
Stem Cell Chatter Despite the promise suggested by early studies, embryonic stem cell research remains highly speculative. More concrete results, not the amount of cash being poured into research, are the best basis for investing decisions. |
| AskMen.com |
Synthetic Sperm Created British scientists claimed Wednesday to have created human sperm from stem cells, but other experts questioned their data. |
The Motley Fool
January 4, 2005
W.D. Crotty |
A StemCell First News of an FDA application sends StemCells' stock soaring. |
Pharmaceutical Executive
October 1, 2012
Ben Comer |
Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures. |
The Motley Fool
April 12, 2010
Brian Orelli |
Pay for Our Drugs or Else Is the pharmaceutical industry's muscle strong enough? In the U.S., health-care reform will increase coverage, but the reform's ability to keep prices in check is fairly limited. |
Reason
October 2001
Ronald Bailey |
Blastocyst Brouhaha Which human cells count as people? |
BusinessWeek
May 24, 2004 |
Michael J. Fox's Take on Stem Cells Opposition to this research is "ridiculous," says the actor. It will happen "in other countries now, and we won't have as much input" |
BusinessWeek
May 24, 2004
Arlene Weintraub |
Want To Bank Your Own Stem Cells? One Los Angeles startup believes everyone should, to be ready when regenerative therapies start hitting the market |
Fast Company
March 2009
Tim McKeough |
Banking Stem Cells For Future Use A personal banking system for stem cells. |
The Motley Fool
January 31, 2011
Brian Orelli |
Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities. |
BusinessWeek
December 29, 2010
Kelley & Cortez |
AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs. |
